D. Boral Capital Reiterates “Buy” Rating for Immunic (NASDAQ:IMUX)

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating reaffirmed by equities research analysts at D. Boral Capital in a report issued on Tuesday,Benzinga reports. They currently have a $17.00 price objective on the stock.

A number of other brokerages also recently issued reports on IMUX. William Blair began coverage on shares of Immunic in a report on Tuesday, March 25th. They set an “outperform” rating on the stock. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Immunic in a report on Friday, February 21st. Finally, StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $12.67.

Immunic Price Performance

Immunic stock opened at $1.11 on Tuesday. Immunic has a one year low of $0.92 and a one year high of $2.11. The business’s fifty day moving average is $1.09 and its 200 day moving average is $1.20. The stock has a market capitalization of $99.99 million, a PE ratio of -0.90 and a beta of 1.89.

Institutional Investors Weigh In On Immunic

Several institutional investors and hedge funds have recently modified their holdings of the stock. Invesco Ltd. bought a new position in shares of Immunic during the fourth quarter worth $37,000. Virtu Financial LLC purchased a new stake in Immunic in the 3rd quarter worth $50,000. HB Wealth Management LLC purchased a new stake in Immunic in the 4th quarter worth $81,000. Barclays PLC bought a new position in shares of Immunic during the 4th quarter valued at about $84,000. Finally, Jane Street Group LLC grew its position in shares of Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after purchasing an additional 38,553 shares in the last quarter. Institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.